therapy has improved outcomes in advanced GISTs. Current guidelines suggest monitoring with CT scanning every 12 weeks. There are no validated biomarkers to assist disease evaluation. We identified 50 patients treated with imatinib for GIST in a single tertiary centre. We assessed the prognostic value of ddimers by Cox regression, and the utility as a biomarker for radiological progression (rPD) using receiveroperator curve (ROC) analysis. In asymptomatic patients with d-dimer levels <1000 and falling levels, the negative predictive value for rPD was 92%. D-dimers may reduce the burden of CT scanning in a proportion of patients in this setting.
Background
The use of imatinib, a molecularly targeted agent against the tyrosine kinase receptor, has led to improved tumour control and a survival advantage in patients with locally advanced and metastatic GISTs [1] [2] [3] . Benefits have also been seen in second line treatment with sunitinib, following progression with, or intolerance of, imatinib. With the availability of second line therapies, disease monitoring whilst on imatinib is important to identify cancer progression in a timely manner. CT scanning is the imaging modality recommended by established guidelines for routine monitoring. Specific guidelines suggest that CT scans to assess response should be performed up to 3 monthly, for an indefinite time period [4] [5] [6] [7] . Such frequent scanning aims to identify progression early, but as patients may remain progression-free for a number of years, it comes with a burden of cost, radiation exposure and consequences for the patient experience. In contrast to other cancers, there are currently no non-radiological biomarkers to aid in the response assessment of GIST.
D-dimers are commonly used in the diagnostic assessment algorithm for the exclusion of venous thrombosis due to their high negative predictive value (NPV) for this condition 8 . They are also raised in other conditions and therefore have a poor positive predictive value (PPV). As a result D-dimers are useful for ruling-out, rather than ruling-in, thrombosis. D-dimers are frequently raised in the presence of active cancer and are associated with poor survival outcomes 9 . For this reason it seems possible that they can help to rule out active or progressing cancer.
D-dimers have been measured approximately 3-monthly in patients with advanced GIST in our centre over the last 10 years. We investigated whether D-dimers can predict disease progression in patient with GIST treated with palliative imatinib therapy. The objective was to determine if D-dimers can offer sufficient negative predictive value for radiological progression to reduce the frequency of CT scanning.
Patients & Methods
Patients were eligible for inclusion in the study if they had been treated with imatinib as palliative treatment for histologically confirmed incurable GIST between 1 st January 2000 and 1 st January 2010. The study was limited to St. James's University Hospital in Leeds, UK which is a single large tertiary referral centre.
Patients were identified retrospectively using a systematic search of an electronic patient records database 
Endpoint definitions
Response assessment was measured by CT scan reported to standard criteria (the adopted criterion in the department was changed from RECIST to Choi in 2004). Clinical benefit was defined as complete response, partial response or stable disease. Day zero was taken as the date of the commencement of imatinib.
Survival endpoints were progression free survival (PFS) and overall survival (OS). PFS was defined as time to first radiological evidence of progression or death from any cause, with patients censored at last follow-up.
OS was defined as time to death from any cause, with patients censored at last follow-up.
The D-dimer measurement associated with each scan was that taken closest to each CT scan date. Any Ddimer measurement that was taken more than 30 days either side of the CT scan was excluded.
Assessment of the ability of D-dimers to exclude radiological progression took two separate approaches.
The first ("D-dimer level") took the reported value at the time of the scan. The second approach ("D-dimer trend") took the difference in the level between two sequential scans, irrespective of the time interval between measurements.
Statistical Analysis
The Kaplan-Meier method was used for survival analysis. A log-rank test was used to test for significant prognostic ability of baseline D-dimer levels. Adjustment for baseline clinical characteristics previously identified as prognostic in advanced GIST was undertaken using the Cox proportional hazards model [11] [12] [13] .
Genetic mutation analysis was not conducted in patients diagnosed early in the series therefore this was not with medians compared using the Wilcoxon rank sum test. The mean change (trend) was compared using a Welch's t-test. A two-sided p-value of less than 0.05, in all tests, was considered statistically significant.
Receiver operating characteristic (ROC) analysis was conducted using established methods 15 . The predictive ability of both the absolute D-dimer level and the trend (change over time) was assessed. R version 2.11.1 was used for the statistical analysis 16 .
Results
A total of 50 patients were included in the study. Patient characteristics are summarized in Table 1 . There were no patients diagnosed with venous thromboembolism during the study period.
The median follow-up at the time of analysis (January 2012) was 3.7 years overall or 4.7 years in patients who remain alive and progression-free. 41 patients (82%) experienced events meeting the definition of PFS. The median PFS was 2.2 years. 29 patients (58%) had died and the median OS was 4.9 years.
D-dimers as a prognostic indicator
A baseline D-dimer measurement of >1000 ng/ml was prognostic for PFS (p = 0.00002, unadjusted hazard ratio 5.55) and OS (p = 0.000007, unadjusted hazard ratio 7.9) (Figure 1 ). This remained significant when adjusted for all other baseline factors in bivariate and multivariable analysis. D-dimers were more strongly prognostic for PFS and OS when analysed as a continuous time-dependent covariate.
D-dimers as a predictor of disease activity
In total, across all patients there were 460 observation points which included a CT scan, D-dimer measurement and clinical assessment. The median D-dimer level when there was no radiological evidence of progression was 411 ng/ml (IQR 233 -691) compared to a median level in patients with radiological evidence of progression of 609 ng/ml (IQR 342 -1770) (p = <0.0001 ). The median level when there was radiological or symptomatic evidence for progression was 1238 ng/ml (IQR 591 -2528) (Figure 2a ).
Looking at the change in D-dimer level compared with that measured at the time of the previous scan (trend), the median change prior to a scan with no evidence of radiological progression was 0 ng/ml (IQR -65 -67).
Patients with radiological evidence of progression had a median change of 80 ng/ml (IQR 0 -339) (p <0.0001). The median level of change when there was both radiological and symptomatic evidence of progression was 189 ng/ml (IQR 0 -892) (Figure 2b ).
ROC curves are presented in Figure 3 for both D-dimer levels, and change in D-dimer levels, demonstrating the sensitivity and specificity as a biomarker for radiological progression. The area under the ROC curve (AUC) was 0.64 and 0.65 respectively.
D-dimers as a surrogate marker to exclude radiological progression
The odds for radiological progression, given different D-dimer levels, change in D-dimer levels prior to a scan, and the presence or absence of clinical symptoms are presented in Figure 4 . Falling D-dimers are The results presented here suggest that D-dimer monitoring offers useful information about progression status. We suggest that a combination of three criteria can be considered reassuring of non-progression: i) no clinical evidence of progression, ii) a fall in the D-dimer level since the previous measurement and, iii) a D-dimer level less than 900 ng/ml. The NPV for progression in patients meeting all these criteria is 0.93.
This suggests that CT scanning can safely be foregone in patients meeting these criteria. The benefits of adopting D-dimer-directed CT scanning would be to reduce the burden of scans by approximately a third.
The negative consequences would be to introduce a delay to diagnosis in around 7% of true progression events. This delay would be incurred until such a time as either the D-dimer level stabilized or rose, or the patient developed symptoms of progression.
Our conclusions make the assumption that our gold-standard test, the CT scan, is a perfect indicator of progression status. However, radiological evaluation is not straight forward for GIST and the interpretation of [18] [19] [20] . We found no data reporting the sensitivity and specificity of imaging modalities for the detection of progression. For these reasons, our reported NPV for Ddimers needs to be interpreted in relation to CT progression detection rather than more meaningful patient outcomes.
There are currently no validated biomarkers to aid in response assessment or detection of progression in
GIST. There are a number of other precedents supporting the use of tumour markers to provide information about progression status. This is perhaps most notable in the case of germ cell tumours, which secrete HCG or -fetoprotein, where tumour markers correlate very strongly with progression and may frequently pre-date radiological detectability; monitoring is a core component of follow-up guidelines 21 . The marker CA-125 is highly correlated with progression status in ovarian cancer 22 and CEA is used to monitor the treatment of colorectal cancer.
The activation of the coagulation system is associated with the immune response that accompanies active malignancy. D-dimer is a fibrin degradation product present in the blood when following the activation of the coagulation cascade. There is therefore a mechanistic theory that supports D-dimers as a biomarker for cancer activity. In a number of published studies, D-dimers have been shown to be related to cancer, with high levels associated with the presence of malignancy, higher levels seen in metastatic compared with earlier stage disease and raised in those with active cancer compared to patients in remission [23] [24] [25] . D-dimer levels and changes have demonstrated a relationship with progression status in other studies in lung cancer and breast cancer 26, 27 . As well as being predictive for progression, our data suggests that a high baseline Ddimer is also a prognostic marker for overall survival and progression-free survival. High D-dimer levels at baseline are a poor prognostic sign in several cancers and predictive of lymph node metastases in breast, colorectal and oesophageal cancers 25, [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] . Interestingly, in one study, D-dimers were more prognostic for survival than CEA in colorectal cancer patients 37 .
We therefore suggest that D-dimers could usefully be incorporated into future baseline staging information and considered in the formulation of future prognostic algorithms. This may in part explain the failure of tumour marker monitoring to impact on clinical outcomes in randomised controlled trials 39 . The methods used in our analysis of D-dimers for GIST demonstrate how decision criteria can maximise the performance of the monitoring test, by combining the absolute level, the rate of change and clinical assessment.
The limitations of this study are that it is a single centre study relying on retrospective data collection. The criteria for interpreting CT tumour status also changed during the 10 years over which our data were collected and this may have led to some inconsistency in reporting and identification of progression dates.
Our data also reflects real-world practice rather than being driven by a research protocol. This has some advantages in generalisability to clinical practice, but the findings may have been compromised by factors such as the variability in D-dimer and CT monitoring frequency and non-standard interpretation of findings.
Clinical management also evolved during our study as new therapeutic options were introduced such as c-kit directed therapy and second line treatments.
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